| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014031487 |
| Title |
Bivalent Inhibitors of Iap Proteins and Therapeutic Methods Using The Same. |
| Abstract |
Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed. |
| Applicant(s) |
THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| Representative Drug(s) |
D0YN1X |
Drug Info
|
IC50 < 100 nM |
[1] |
| Patent ID |
WO2011098904 |
| Title |
Iap Bir Domain Binding Compounds. |
| Abstract |
A compound of Formula 1 : (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods. |
| Applicant(s) |
Pharmascience Inc |
| Representative Drug(s) |
D0R3YM |
Drug Info
|
Ki < 25 nM |
[1] |
| Patent ID |
WO2011050068 |
| Title |
Bivalent Diazo Bicyclic Smac Mimetics and The Uses Thereof. |
| Abstract |
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer. |
| Applicant(s) |
The Regents of the University of Michigan |
| Representative Drug(s) |
D0HY5Q |
Drug Info
|
IC50 < 20 nM |
[1] |
| Patent ID |
WO2010142994 |
| Title |
2, 3-Dihydro-1H-Indene Compounds and Their Use To Treat Cancer. |
| Abstract |
Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers. |
| Applicant(s) |
Astrazeneca Ab |
| Representative Drug(s) |
D0B6KC |
Drug Info
|
IC50 = 21 nM |
[1] |
